EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.

View source ↗

Summary

Authorization of Retsevmo (selpercatinib) by EMA for use in non-small cell lung cancer and thyroid neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Neoplasms

Drugs mentioned

• Retsevmo (selpercatinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms. MAH: Eli Lilly Nederland B.V.. Decision date: 04/06/2026